Premium
Sequential molecularly targeted drug therapy including axitinib for a patient with end‐stage renal failure and metastatic renal cell carcinoma
Author(s) -
Nishida Hayato,
Fukuhara Hiroki,
Yamagishi Atsushi,
Sakurai Toshihiko,
Shibasaki Tomohiro,
Kawazoe Hisashi,
Kato Tomoyuki,
Tomita Yoshihiko
Publication year - 2016
Publication title -
hemodialysis international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.658
H-Index - 47
eISSN - 1542-4758
pISSN - 1492-7535
DOI - 10.1111/hdi.12329
Subject(s) - axitinib , medicine , sunitinib , sorafenib , renal cell carcinoma , everolimus , targeted therapy , hemodialysis , adverse effect , oncology , end stage renal disease , stage (stratigraphy) , urology , cancer , hepatocellular carcinoma , paleontology , biology
A 62‐year‐old male patient with end‐stage renal disease and metastatic renal cell carcinoma ( RCC ) was referred to our hospital. Sequential targeted therapy consisting of sorafenib, sunitinib, and everolimus was administered, but the patient's disease gradually progressed. Axitinib was subsequently administered at a decreased dose of 6 mg/day for 2 weeks, after which the dose was escalated to 10 mg/day. Axitinib therapy was maintained for a total of 6 months without severe adverse effects. Sequential molecularly targeted drug therapy including axitinib, with careful monitoring, is one possible treatment option for patients with metastatic RCC with renal impairment.